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Systemically-administered dopaminergic drugs have been found to facilitate sexual behavior of men and male rats. The present ex- 
periments investigated the localization within the brain of dopaminergic effects on copulation of male rats. Apomorphine, a dopamine 
agonist, was microinfused into the medial preoptic area, caudate-putamen,  nucleus accumbens, lateral septum and lateral ventricle. 
The lowest dose of apomorphine (0.2 pg) infused into the ventricle reduced the number of ejaculations, slowed the rate of intromitting 
and decreased the percentage of mounts on which the male gained vaginal intromission. The higher two doses (0.5 and 2.0/~g) infused 
into the medial preoptic area and, in some cases, the ventricle, increased the number of ejaculations and the percentage of mounts 
with vaginal intromission, increased the rate of intromitting and decreased the latency to ejaculate and the postejaculatory interval be- 
fore resuming copulation. Infusions into the caudate-putamen and lateral septum were without effect. Those into nucleus accumbens 
produced only a slight dose-related decrease in latency to begin copulating. The copulatory impairments associated with infusions of 
the lowest dose into the ventricle may have resulted from stimulation of autoreceptors, or from preferential stimulation by low doses of 
an undetermined area. The facilitative effects of the two higher doses into the medial preoptic area and lateral ventricle may have been 
due to stimulation of dopaminergic postsynaptic receptors. 
INTRODUCTION 
Dopaminergic drugs, administered systemically in 
relatively low  doses,  have  been found to  facilitate 
masculine sexual behavior in both men and rats. For 
example, L-DOPA has been found to induce hyper- 
sexuality in men with Parkinson's diseaseS,lo,32 and to 
relieve impotence associated with diabetes in some 
patients  29.  Following the initial reports of sexual fa- 
cilitation in humans, Malmnas24,25  found that several 
dopaminergic drugs also facilitated the sexual behav- 
ior of male rats.  Conversely, drugs  that  decreased 
dopaminergic activity impaired masculine sexual be- 
havior24,25.  These  effects  have  been confirmed and 
extended  in  several  laboratoriesl,6.12,14.17,26.31  (but 
see refs. 2, 20). 
A problem with systemically-administered  drugs is 
that they may affect numerous neural systems simul- 
taneously.  It  is  not  clear which  dopaminergic syn- 
apses mediate the drug effects. It has been suggested 
that the nigrostriatal tract, ascending from substantia 
nigra to the caudate-putamen (CP) is the most likely 
site of dopaminergic facilitation of male sex behav- 
ior  1t,15,26. This suggestion was  based  largely on the 
observation that  chemical or  electrolytic lesions of 
this tract impaired masculine sexual behavior, along 
with other active motor patterns. 
Two additional sites at which dopamine might in- 
fluence sexual behavior are  the nucleus accumbens 
(NA)  and the  lateral septum (LS);  both are  major 
terminations of mesolimbic dopamine containing ax- 
ons. Alderson and Baum3 reported that castration of 
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male  rats  reduced  the  concentrations  of dopamine 
and its metabolites in NA and the septal area, but did 
not alter dopamine metabolism in the CP. This find- 
ing suggested a role for the mesolimbic tract in some 
aspect  of  testosterone-related  (presumably  mascu- 
line)  function.  Furthermore,  implantation  of dihy- 
drotestosterone propionate into the LS facilitated co- 
pulation  in  castrated  male rats  given estradiol  sys- 
temically  7. 
A  fourth potential site for dopaminergic influence 
is the medial preoptic area (MPOA), long recognized 
as  critical  for  masculine  sexual  behavior  13,18,21.  A 
small group of dopaminergic axons of the incertohy- 
pothalamic  tract  terminate  in  the  MPOA  9.  Since 
these neurons are small in both size and number, they 
are frequently overlooked in discussions of dopamine 
tracts; however, their location in an area important 
for masculine sexual behavior suggests that they may 
play a role in its regulation. 
The experiments described here tested the relative 
efficacy of microinfusions of the  dopamine  agonist 
apomorphine (APO)  into the  MPOA,  the NA,  the 
CP and the LS. In addition, infusions were made into 
the lateral ventricle (LV), as a control site.  In addi- 
tion, these experiments investigated whether various 
components of masculine sexual behavior were dif- 
ferentially affected. 
MATERIALS AND METHODS 
Animals 
Adult  male  Long-Evans  rats  (300-350  g),  pur- 
chased  from  Blue  Spruce  Farms  (Altamont,  NY), 
were  caged  singly  in  large  plastic  cages in  a  room 
where  lights  were  off between  11.00  and  21.00  h. 
Food and water were available ad libitum.  Animals 
were  handled  daily  so  that  intracerebral  infusions 
could be accomplished without stress or anesthesia. 
Males were screened on two preoperative tests for a 
moderate level of sexual behavior (one or two ejacu- 
lations per test). Stimulus females of the same strain 
were ovariectomized under Metofane anesthesia and 
housed in a separate room. Forty-eight hours before 
a  behavioral  test  females  were  injected  subcuta- 
neously with 20/~g estradiol benzoate in oil; 4 h be- 
fore the test they received a subcutaneous injection 
of 500~g progesterone in oil. 
Surgery and cannulae 
Forty-four male rats, divided into two groups of 28 
(Experiment 1) and 16 (Experiment 2), received two 
stainless-steel  cannulae,  one  ending  1.0  mm above 
the left MPOA (AP 2.4, ML 0.2, DV -6.6), the oth- 
er, within the right LV (AP 0.0, ML 1.5, DV -2.8). 
For Experiment 3, one group of 18 animals had a sin- 
gle cannula ending  1.0  mm above the NA (AP 3.2, 
ML 1.5, DV -5.5); a second group of 17 males had a 
single cannula ending in the largest extent of the CP 
(AP-2.2,  ML 3.0, DV -3.5).  For Experiment 4,  14 
males had a single cannula ending in the LS (AP 2.4, 
ML 0.2,  DV -4.6).  (All placements were based on 
coordinates  of Pellegrino  et  al.2S.)  Implantation  of 
the outer guide cannulae was done under pentobarbi- 
tal anesthesia,  using a  Kopf stereotaxic frame with 
the incisor bar 5 mm above the interaural line. After 
shaving, cleaning and exposing the skull, a small hole 
was drilled over the appropriate structure.  Cannulae 
were lowered to the predetermined depth, using the 
stereotaxic drive.  Four  small  stainless-steel  screws, 
drilled barely through the skull, provided anchorage 
for  the  assembly.  Dental  cement  surrounded  the 
screws and the guide cannula. 
Guide  cannulae  were  constructed  from 23-gauge 
thin-wall hypodermic tubing, cut to the length appro- 
priate  for each  placement  and  sanded  on  a  rotary 
sanding disk.  Each guide cannula was fitted with an 
obturator  constructed  from  27-gauge  hypodermic 
tubing.  A  collar  of  23-gauge  tubing  was  crimped 
around the top to prevent the obturator from extend- 
ing more than  1.0 mm beyond the end of the guide 
cannula.  A  small length of polyethylene tubing was 
fitted over both the collar and the top of the guide 
tubing to make an airtight  seal.  The cannulae  used 
for infusions were made from 28-gauge hypodermic 
tubing. One end of a  1-m length of polyethylene tub- 
ing was fitted over the end of the infusion cannula, 
thereby  preventing  it  from extending  more  than  1 
mm below the end of the guide cannula.  At the time 
of drug administration the other end of the polyethyl- 
ene tubing was connected to a 1-ml syringe held in a 
Kopf microinfusion pump. 
Drugs 
Apomorphine was mixed with vehicle immediately 
before each test.  The vehicle for Experiment 1 was 
isotonic  saline  with  0.2%  ascorbic  acid.  Since  the drug appeared to be incompletely dissolved in the sa- 
line vehicle, distilled water with 0.2%  ascorbic acid 
was used for Experiments 2, 3 and 4. The volume of 
each infusion was 0.5/d. 
Procedures 
At  1 and 2  weeks after surgery males were given 
baseline  tests  with  a  receptive  female.  Thereafter, 
animals were  given weekly drug  tests, with the ap- 
propriate drug dose or vehicle being infused immedi- 
ately before each  test.  Testing occurred from  14.00 
to  16.00  h.  Infusion was accomplished by removing 
the entire obturator assembly from the guide cannula 
and replacing it with the infusion cannula.  Infusions 
were administered over a  30-s interval, followed by 
an  additional 30-s  with  the  infusion cannula  left in 
place. The infusion cannula was then  replaced with 
the obturator, and the male was returned to his home 
cage.  He  was  then  taken  to  a  testing room,  and  a 
stimulus female was introduced into his cage. 
Each test lasted for 30 rain after the male's first in- 
tromission, or for 30 min after introduction of the fe- 
male  if  no  intromission  occurred.  The  following 
measures were  recorded: latency to first mount,  la- 
tency to  first intromission,  latency from  first intro- 
mission  to  first  ejaculation  (ejaculation  latency), 
postejaculatory  interval  before  the  next  intromis- 
sion, intromissions/mounts plus intromissions (intro- 
mission ratio), intromissions preceding each ejacula- 
tion  (intromission  frequency),  number  of  ejacula- 
tions  during  the  test  (ejaculation  frequency),  and 
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mean interval between intromissions (inter-intromis- 
sion interval). Animals that failed to copulate were 
excluded  from  all  analyses  except  ejaculation  fre- 
quency.  Intromissions were  distinguished behavior- 
ally from mounts by the presence of a  rapid, spring- 
ing dismount.  Ejaculation patterns were  character- 
ized by longer, deeper thrusts, slow dismounts and a 
prolonged  period  of rest  (postejaculatory interval) 
following the ejaculation. 
Histology 
After all behavioral tests were  completed,  males 
were  anesthetized  and  sacrificed  by  decapitation. 
Brain slabs were removed and mounted in an Ameri- 
can Optical cryostat. Coronal sections were cut at 40 
/~m, mounted on glass slides, stained with cresyl vio- 
let, and examined with a projection magnifier. Data 
from animals whose LV cannulae missed the ventri- 
cle were  omitted from  analyses of ventricular infu- 
sion effects. All MPOA,  NA and CP cannulae were 
within approximately 0.5 mm of their intended sites; 
no data were excluded from these analyses. Exami- 
nation of dye diffusion in other animals has suggested 
that diffusion of 0.5/tl within tissue is confined to a 
volume approximately 0.5 mm in radius. 
EXPERIMENT  1.  EFFECTS  ON  COPULATION  OF 0.2 
AND 0.5 gg APO IN MPOA AND LV 
Twenty-eight animals with MPOA  and LV cannu- 
lae were divided into two groups; one group (n =  13) 
TABLE I 
Effects of apomorphine vs vehicle infusions into the rnedial preoptic area or lateral ventricle on masculine sexual behavior, Experiment 1 
Values are the means + S.E.M. for significantly-affected variables analyzed by t-test for each cannula site. EF, ejaculation frequency; 
IR, intromission ratio; III, inter-intromission  interval. 
MPOA  LV 
n  Vehicle  0.2 l~g APO  n  Vehicle  0.2 ~g APO 
EF  13  2.15 _+ 0.27  1.69 + 0.29  10  2.40 + 0.22  1.50 + 0.27** 
IR  9  66.8 _+ 2.1  66.6 + 2.8  9  79.8 + 3.5  66.4 + 4.9* 
III  9  41.6 _+ 8.1  33.9 + 4.3  9  26.9 + 1.7  46.2 + 8.0* 
MPOA  L V 
n  Vehicle  0.5 Itg A PO  n  Vehicle  O. 5 t~g A PO 
EF  15  1.73 + 0.23  2.47 + 0.17"  13  1.64 + 0.36  1.79 + 0.33 
IR  13  66.2 _+ 5.0  73.5 + 6.7*  8  71.4 + 4.7  84.9 + 7.0* 
III  13  51.0 + 6.5  30.9 + 3.3*  8  29.1 + 3.5  24.6 + 2.6 
* P< 0.05; ** P< 0,01. 76 
received either 0.2 #g APO  or the ascorbate saline 
vehicle into either the MPOA or the LV cannula be- 
fore each  test.  The  other group  (n  =  15)  received 
either 0.5/tg APO or vehicle into one of the two can- 
nulae  before  each  test.  Each  animal  was  tested  4 
times, with a  total of two infusions per cannula.  All 
treatments  were  counterbalanced.  Statistical  com- 
parisons of APO vs vehicle were based on correlated 
t  tests,  computed  separately for  each  cannula  site 
within each group of animals. 
Results 
Effects of APO infusions varied with both dose and 
site. The higher dose (0.5/~g) infused into the MPOA 
significantly  increased  both  ejaculation  frequency 
(t =  2.65, df =  14, P  <  0.02)  and intromission ratio 
(t =  2.71, df =  12, P  <  0.02), and decreased inter-in- 
tromission interval (i.e. speeded the rate of intromit- 
ting) (t =  2.69, df =  12, P  <  0.02). (See Table I.) The 
higher ejaculation frequency was in part due to an in- 
crease in number  of animals  achieving at least one 
ejaculation  (87%  with  vehicle,  100%  with  0.5  /tg 
APO),  and in part to a  trend towards greater num- 
bers of ejaculations achieved by those  animals that 
did exhibit the behavior (t =  1.9, df =  12, 0.1 >  P  > 
0.05). When infused into the LV this dose significant- 
ly elevated only intromission ratio (t =  2.78, df =  7, P 
<  0.05). On the other hand, infusions of the low dose 
(0.2/~g) into the LV significantly decreased both eja- 
culation frequency (t =  3.25, df =  9, P  <  0.01) and in- 
tromission ratio (t =  2.85, df =  8, P  <  0.05), and in- 
creased  inter-intromission  interval  (i.e.  slowed  the 
rate of intromitting) (t =  2.31, df =  8, P  <  0.05). The 
decrease  in  numbers  of ejaculations observed with 
MPOA infusions of this dose was not statistically sig- 
nificant; no other measures were affected. 
EXPERIMENT  2.  EFFECTS  ON  COPULATION  OF 0.5 
AND 2.0/~g APO IN MPOA AND LV 
Experiment 2 was designed both to extend the do- 
se-response curve and to confirm the previous facili- 
tative effects of the 0.5/~g dose, using the ascorbate 
water vehicle. Sixteen animals with MPOA  and LV 
cannulae were tested a  total of 6 times each, with 3 
infusions per cannula.  Doses were 0.0 (vehicle), 0.5 
and 2.0 #g APO. All animals received all treatments 
in counterbalanced order. One-way analyses of vari- 
ance,  with  repeated  measures  on  the  dose  factor, 
were computed separately for each cannula site.  In 
addition,  Cochran's  Q  tests  for  repeated  obser- 
vations were used to compare numbers of animals in 
each treatment that achieved one, two or 3 ejacula- 
tions per test.  Finally, since the number  of animals 
that  consistently achieved  at  least two  ejaculations 
was relatively low, data from all these animals were 
combined in a single two-way analysis of variance for 
ejaculation  latency  and  postejaculatory interval  of 
the second ejaculation. 
Results 
In this group  of MPOA/LV  animals, the facilita- 
tion by the 0.5 ~g dose of APO was confirmed, and 
was observed with the 2.0/~g dose as well. (See Table 
TABLE II 
Effects of  apomorphine vs vehicle infusions into the medial preoptic area or lateral ventricles on masculine sexual behavior, Experiment2 
Values are the means + S.E.M. for significantly-affected variables. EF, ejaculation frequency; PEI1, postejaculatory  interval follow- 
ing the first ejaculation (s); EL2, ejaculation latency to the second ejaculation (s); PEI2, postejaculatory  interval following the second 
ejaculation (s). 
MPOA  L V 
n  Vehicle  0.5ktgAPO  2.01~gAPO  n  Vehicle  0.51~gAPO  2.0ktgAPO 
EF  16  1.94 _+ 0.23  2.69 _+ 0.15"*  2.63 + 0.13"*  10  1.20 + 0.33  2.30 _+ 0.37*  2.40 + 0.22* 
PEI1  14  469.0  + 34.6  382.6 + 26.6*  399.0 + 17.0  5  494.2 + 37.4  428.4 + 73.8  422.0 + 26.4 
EL2  13  248.2 + 34.1  166.2 + 13.3"  237.9  + 32.7  4  301.8 + 61.8  136.0 +_ 13.6"  159.8 + 23.8* 
PEI2  13  590.0 _+ 40.2  506.9 _+ 45.8  491.7 + 16.2"  4  630.5 + 34.8  441.5 + 27.7*  488.3 + 40.5* 
EF I> 2  16  13  16"  16"  10  6  8  9 
EF/> 3  16  4  10"  10"  10  0  5*  5* 
*  P<0.05;**P<0.01. II.)  Ejaculation  frequency  was  increased  by  both 
doses infused into both sites (MPOA, F =  7.05, df = 
2,30, P  <  0.01; LV, F  =  5.05, df =  2,18, P  <  0.05). 
The increased  ejaculation  frequency observed with 
MPOA  infusions  was  statistically  significant  even 
when only data from animals that did ejaculate were 
analyzed (F =  4.28, df =  2,26, P  <  0.05).  A  similar 
trend  for LV infusions failed to reach significance, 
using  only  data  from  animals  that  did  ejaculate. 
Cochran's Q  comparisons showed  that significantly 
more animals achieved at least two ejaculations (Q = 
6, df =  2, P <  0.05) and more achieved at least 3 eja- 
culations (Q =  6, df =  2, P <  0.05) after MPOA infu- 
sions of APO than after vehicle infusions. Similarly, 
more animals ejaculated at least 3 times with LV in- 
fusions of APO than with vehicle infusions (Q =  7.4, 
df =  2, P <  0.05). In addition, the postejaculatory in- 
terval after both the first (MPOA,  F  =  3.47,  df = 
2,26, P  <  0.05; LV, F  =  1.11, n.s.) and second (F = 
6.07,  df =  2,62,  P  <  0.01)  ejaculations was short- 
ened,  and  latency  to  the  second  ejaculation  (F  = 
3.21, df =  2,62, P  <  0.05) was also shortened.  (Only 
the significant main effect for dose is presented; nei- 
ther the main effect for cannula site nor the interac- 
tion was significant.) 
EXPERIMENT 3.  EFFECTS OF APO INFUSIONS INTO 
CP AND NA 
Since LV infusions in  the preceding experiments 
affected several copulatory measures, Experiment 3 
was  conducted  to  ascertain  whether  those  effects 
were mediated by either the NA or the CP. The 17 
animals with single CP cannulae and the 18 animals 
with single NA cannulae were tested a total of 3 times 
each, after infusions of 0.0 (ascorbate water vehicle), 
0.5 and 2.0 gg APO, in counterbalanced order. One- 
way analyses of variance, with repeated measures on 
the dose factor, were used for each group of animals. 
Results 
Infusions of APO into the CP had no effect on mas- 
culine sexual behavior; nor did they produce any ob- 
vious effects on motor behavior.  Infusions into the 
NA produced a dose-related decrease in intromission 
latency; however this effect was of borderline statis- 
tical significance  (vehicle,  407.2  s;  0.2/~g,  261.7  s; 
0.5/tg,  152.5  s; 2.0/~g,  127.1  s; F  =  2.66, df =  3,56, 
77 
P =  0.058). No other measures were affected. 
EXPERIMENT 4.  EFFECTS OF APO INFUSIONS INTO 
LS 
Since the effects of ventricular infusions appeared 
not to be mediated by either the  CP or the NA,  a 
fourth experiment was conducted to test the effects 
of septal infusions. The coordinates for these cannu- 
lae were almost identical to those used by Baum et 
al.7  to demonstrate facilitation  of masculine  sexual 
behavior by septal implants of dihydrotestosterone. 
Furthermore, they were the same as those used for 
the MPOA cannulae in Experiments 1 and 2, except 
that septal cannulae ended 2 mm more dorsal. Thus, 
Experiment 4 was designed to answer two questions: 
(1) whether infusions of APO into the LS affected co- 
pulation; and (2) whether the effects of MPOA infu- 
sions in previous experiments might have been me- 
diated by drug diffusing up the cannula track. 
Fourteen  males  received  unilateral  cannulae 
aimed at the anterior end of the LS. Data from 3 ani- 
mals were later discarded because of inaccurate can- 
nula placement. Each animal was tested 5 times, af- 
ter infusions of 0.0,  0.2, 0.5, 2.0 or 4.0/~g APO, in 
counterbalanced  order.  Data were  analyzed with  a 
one-way  analysis  of variance  with  repeated  meas- 
ures. 
Results 
Infusions of APO into the LS had no effect on any 
parameter of sexual behavior. 
DISCUSSION 
Ill Experiments 1 and 2, several copulatory meas- 
ures were  affected by infusions of APO.  These in- 
cluded ejaculation frequency, intromission ratio, in- 
ter-intromission  interval,  ejaculation  latency,  and 
postejaculatory interval.  The complexity of mascu- 
line  sexual behavior contributes  to the  difficulty of 
studying the mechanisms that regulate it. Beach8 ar- 
gued that male sexual behavior should not be consid- 
ered a  unitary  construct,  but  rather that  it is com- 
posed of at least two separate mechanisms. The sex- 
ual arousal mechanism was hypothesized to control 
the male's initiation of copulation as well as his re- 
sumption of it following an ejaculation.  The copula- 78 
tory mechanism was assumed to summate the excita- 
tory effects of repeated intromissions and to maintain 
the  series of intromissions until  they culminated  in 
ejaculation.  Additional  complexity  was  noted  by 
Sachs  30, who further analyzed the copulatory mecha- 
nism into several components: a copulatory rate fac- 
tor (inter-intromission  interval,  ejaculation latency, 
and postejaculatory interval), a hit rate factor (per- 
centage of attempts on which the male gained intro- 
mission), and an intromission count factor (number 
of intromissions per ejaculation).  He also suggested 
that the neural mechanisms regulating these various 
factors  may  be  differentially  localized  within  the 
brain. The present experiments were designed to as- 
sess the possibility of such differential localization. 
The  major site-dependent  effect in  these  experi- 
ments was the impairment of copulation by the low- 
est dose of APO only when it was infused  into the 
LV. This impairment was manifested as a decline in 
ejaculation frequency and in intromission ratio, and a 
lengthening  of  inter-intromission  interval;  all  are 
measures of a  copulatory mechanism (or,  in  Sachs' 
terms, a copulatory rate factor and a hit rate, or in- 
tromission ratio, factor; Sachs did not discuss ejacu- 
lation  frequency30).  One  possible  explanation  for 
these results is that a site other than the MPOA or the 
LS, presumably in close contact with the ventricular 
circulation,  mediates  the  inhibitory  effects  of  low 
doses of APO on a copulatory mechanism. (The low- 
est dose was not tested in the CP or the NA.) A  sec- 
ond possible explanation will be discussed below. 
On  the  other hand,  the  facilitative effects of the 
two  higher  doses  were  in  most  cases  similar  for 
MPOA and LV infusions. There are at least 3 possi- 
ble  explanations  for this  similarity.  First,  APO  in- 
fused into the MPOA may have leaked into the ven- 
tricular  circulation  and  produced  its  effects on  the 
same structure(s) as did LV infusions. Alternatively, 
APO infused into the ventricles may have acted on 
the MPOA. The third possibility is that several struc- 
tures may act in concert in dopaminergic regulation 
of sexual behavior, and were affected similarly by the 
drug. In an attempt to resolve these conflicting inter- 
pretations, we tested the effectiveness of APO infu- 
sions  into  3  major dopamine-containing  areas,  the 
CP,  the  NA  and  the  LS,  in  Experiments  3  and  4. 
However, infusions into these  sites failed to repro- 
duce the effects of infusions into the MPOA or the 
LV. Infusions into the CP and LS failed to affect any 
aspect  of behavior.  Infusions  into  the  NA  did  de- 
crease intromission latency in a dose-dependent fash- 
ion; however, the effect was of only borderline statis- 
tical  significance  and  no  other  measures  were  af- 
fected. Therefore, the structure(s) mediating the ef- 
fects of ventricular infusions is (are) not known. The 
MPOA may be important for at least the facilitative 
effects, but the CP, the NA and the LS appear not to 
play a major role. 
The effects of APO infusions into the MPOA and 
LV were dose-dependent.  On several measures one 
or both of the two higher doses facilitated a copulato- 
ry mechanism, while the  lower dose in the LV im- 
paired its function.  Specifically, the 0.5  and 2.0/ag 
doses  increased  ejaculation  frequency  in  Experi- 
ments 1 and 2, and the 0.5/~g dose increased intro- 
mission ratio and decreased inter-intromission inter- 
val in Experiment  1;  both doses decreased ejacula- 
tion latency and postejaculatory interval in Experi- 
ment 2. 
On the other hand,  the lowest dose of APO  (0.2 
#g) decreased both ejaculation frequency and intro- 
mission ratio  when  infused  into  the  LV in  Experi- 
ment 1, and also significantly slowed the rate of intro- 
mitring. All of these effects may be interpreted as an 
impairment  of a  copulatory  mechanism.  As  noted 
above, one possible explanation of this pattern of ef- 
fects is that one or more structures in contact with the 
ventricles are very sensitive to low doses of APO and 
interfered  with  a  copulatory  mechanism.  The 
MPOA, according to this hypothesis may be less sen- 
sitive to low doses, but higher doses activate its facili- 
tative  effects.  A  second  possible  explanation  sug- 
gests that both inhibitory and facilitative effects may 
be exerted  by the  same structure(s);  however,  the 
lowest dose of APO may have activated, primarily, 
the more sensitive autoreceptors, thereby decreasing 
the output of endogenous dopamine and impairing co- 
pulation. The higher doses may have been sufficient 
to activate postsynaptic receptors, thereby facilitat- 
ing the behavior. The lack of impairment produced 
by infusions into the MPOA may have resulted from 
an inappropriate choice of dose. Thus, 0.2pg infused 
into the LV would have been diluted by cerebrospi- 
nal fluid and therefore would have been less concen- 
trated at the  active structure(s).  The same dose in- 
fused directly into the MPOA, then, might have been sufficiently concentrated to stimulate  at least some 
postsynaptic receptors, thereby cancelling the inhibi- 
tory effects of autoreceptor stimulation. The obser- 
vation  that  in  Experiment  1  the  same  copulatory 
measures were affected in opposite directions by the 
two doses is compatible with this hypothesis. More 
direct tests of the hypothesis are planned. 
The opposite hypothesis has been previously pro- 
posed, namely that facilitative effects of dopaminer- 
gic agonists on sex behavior are exerted via autore- 
ceptor activation16, 27, while stimulation of postsynap- 
tic receptors impairs copulation  16, Both reports sug- 
gesting that autoreceptor activation reduced ejacula- 
tory threshold rested on assumptions  that their low 
doses of dopamine agonists stimulated only autore- 
ceptors16, 27.  However, convincing evidence that the 
drug doses they used did indeed stimulate only auto- 
receptors in the relevant systems was not presented. 
Their assumption that only autoreceptors were stim- 
ulated was  based on the fact that their doses were 
lower than those needed to induce stereotypy and hy- 
peractivity, and may even have been capable of in- 
ducing sedation (an effect thought to be mediated by 
stimulation  of autoreceptors), although  neither pa- 
per presented data on this measure.  However, the 
use of sedation as a general indicator of autoreceptor 
stimulation has recently been questioned  4.  Further- 
more, the  dopaminergic systems regulating mascu- 
line sexual behavior may be affected by a lower range 
of doses than  those  capable  of inducing  abnormal 
motor patterns.  In  the  present  study the  doses  of 
APO  were  one  to  two  orders of magnitude  lower 
than those that have been infused into the CP or ol- 
factory tubercles to induce contralateral rotation or 
stereotypy, respectively  19. Additional evidence con- 
sistent with our interpretation is the finding that at 
the  lowest  doses  administered  (systemically),  the 
specific dopamine (D-2) agonist LY163502 inhibited 
the sexual behavior of male rats, while higher doses 
facilitated their behaviorl7 (Foreman, personal com- 
munication).  Furthermore,  the  doses  that  affected 
sexual  behavior were  several  orders  of magnitude 
lower  than  those  that  induced  hypoactivity;  and 
those doses, in turn, were much lower than those that 
induced hyperactivity or stereotypy. Thus, both mas- 
culine sexual behavior and locomotor activity may be 
characterized  by  biphasic  dose-response  curves, 
with lower doses of dopamine agonists inhibiting the 
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behavior and  higher doses increasing it.  However, 
the whole dose-response curve for sex behavior may 
be displaced towards the low end of the dose range. 
Additional evidence against the interpretation that 
dopamine autoreceptor stimulation facilitates sexual 
behavior was presented by Ahlenius  and Larsson  1. 
They administered the enantiomers of 3-PPP (initial- 
ly thought to be a specific autoreceptor agonist) sepa- 
rately, and found that only the unselective dopamine 
agonist (+)-3-PPP decreased both ejaculation laten- 
cy and intromissions per ejaculation.  These effects 
were interpreted as a facilitation of sexual behavior, 
i.e. increased efficiency of a copulatory mechanism. 
The (-)  enantiomer, which is  thought to stimulate 
dopamine autoreceptors (and block postsynaptic re- 
ceptors) failed to affect sexual behavior. The lack of 
an inhibitory effect by the (-) enantiomer appears in- 
consistent with our interpretation of autoreceptor-in- 
duced impairment of a copulatory mechanism. How- 
ever, the 3 measures on which we observed impair- 
ment by our lowest dose (ejaculation frequency, in- 
tromission ratio and inter-intromission interval) were 
not recorded by Ahlenius and Larsson. 
The proposap6 that postsynaptic dopamine recep- 
tor  stimulation  impairs  masculine  sexual  behavior 
was based largely on the observation that relatively 
large  doses  of  systemically-administered  apomor- 
phine  suppressed  copulation  in  sexually  vigorous 
rats. However, large doses of dopamine agonists elic- 
it hyperactivity and stereotyped movements that in- 
terfere with sexual behavior1,  24. 
Finally, some of the  apparent  discrepancies con- 
cerning doses that facilitate, versus those that impair, 
sexual behavior may be resolved by noting the partic- 
ular behavioral measures affected. Perhaps the most 
commonly reported effect is a decrease in intromis- 
sion frequency, observed both with dopamine agon- 
ists and antagonists, frequently accompanied by a de- 
crease in ejaculation latency, and usually interpreted 
as a facilitation of sexual behavior1,14,27,31. However, 
none of our intracerebral APO infusions affected in- 
tromission  frequency.  The  dopaminergic  neurons 
regulating  intromission  frequency may  be  located 
outside the areas reached by our infusions.  Sachs  30 
suggested that  the corticomedial amygdala and the 
bed nucleus of stria terminalis may be especially im- 
portant  for  control  of intromission  frequency.  In- 
deed,  we  have  observed decreases  in  intromission 80 
frequency  with  cholinergic  agonists  infused  some- 
what more laterally in the preoptic area, near the bed 
nucleus  of  stria  terminalis22,  23.  The  reason  for  the 
lack of effect on this measure in the present experi- 
ments is not clear. Ejaculation frequency, on the oth- 
er hand, was consistently affected by APO infusions 
into both the MPOA and LV, being decreased by the 
lowest dose  (in  the  LV)  and  increased  by  the  two 
higher  ones.  Our  observation  that  the  two  higher 
doses of APO decreased ejaculation latency, poste- 
jaculatory interval, and (in Experiment 3) intromis- 
sion latency,  is,  as expected,  the  inverse of others' 
findings that  drugs  or  lesions that  decreased  dopa- 
minergic  activity  increased  these  measures6,12, 26. 
Similarly, our interpretation that the slower rate of 
intromitting observed with our lowest dose resulted 
from reduced dopaminergic activity is consistent with 
observations that dopamine antagonists also slowed 
the rate of intromitting6,1L 
The  results  reported  here  suggest  that  small  in- 
creases  in  dopaminergic  activity  facilitate  several 
measures  of  a  copulatory  mechanism.  Both  de- 
creases  in  dopaminergic  activity  (via  autoreceptor 
activation  or  postsynaptic  blockade)  and  large  in- 
creases  that  activate  competing  behavior  patterns 
may  impair  this  mechanism.  Furthermore,  the 
MPOA, and perhaps other structures with direct ac- 
cess to ventricular circulation, may be important in 
dopaminergic regulation of sexual behavior. Howev- 
er, at the doses tested here, there is no evidence that 
dopaminergic synapses in the CP and the LS regulate 
copulation specifically. The importance of the NA in 
this  respect  is  still uncertain.  Multiple  sites  in  the 
brain, spinal cord and periphery, may interact in do- 
paminergic regulation of masculine sexual behavior; 
the dose-response curves, receptor mechanisms and 
copulatory parameters affected, may be different in 
these various sites. 
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